Steritas is very pleased to have been named Startup of the Year during the 2023 SAMPS Awards. The annual SAMPS awards celebrate companies that are doing important work in the life science and applied research industry, and Steritas was recognized among dozens of the best this industry has to offer.

Laura Haldane of SciLeads presented the award, acknowledging how many clinical trials Steritas was supporting with the measurement and monitoring of steroid-toxicity to enable the development of steroid-sparing therapies, optimization of steroid-prescribing patterns across health systems, and empowerment of patients worldwide to engage in their own care. 

“We are surprised and pleased to have been named startup of the year and to be part of the worldwide effort to reduce steroid-toxicity,” said Martha Stone, CEO of Steritas. “This award is a testament to the hard work of our dozens of partners across the world who have joined in our mission and vision of a world free of steroid dependency."

"Steritas is currently supporting academia and biopharma in more than 80 clinical trials, across 23 disease states and in more than 80 countries. The new drugs, treatment protocols and increased awareness being driven by our partners will help millions of patients worldwide.”